Last checked at 7 Nov 2017 12:59
The announcement released by Allergy Therapeutics plc entitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as £0.0001 per share. The correct exercise price is £0.001. All other figures remain unchanged. The correct figure is included in the reissued announcement below:
07 November 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2017, details of which were announced on 5 November 2014, have been met. Consequently, Allergy Therapeutics has today granted to certain employees of the Company, including a PDMR, low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP. Details of the grant of Options to the PDMR are as follows:
Director | Number of Ordinary Shares over which Options granted | Total number of Ordinary Shares over which Options granted | Total remaining number of Ordinary Shares provisionally awarded under LTIPs |
|
|
|
|
Manuel Llobet, Chief Executive Officer | 626,399 | 626,399 | 1,690,000 |
The Options have been granted in accordance with the LTIP rules with an exercise price of £0.001 per share, and can be exercised between 07 November 2017 and 06 November 2027.
Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Manuel Llobet | ||||
2
| Reason for the notification Grant of Options
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| ALLERGY THERAPEUTICS PLC | ||||
b)
| LEI
| 213800PQ7AHK7KGVOE23 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Options over Ordinary Shares of £0.001 each
GB00B02LCQ05 | ||||
b)
| Nature of the transaction
| Grant of Options | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
626,399 Options
£0.001
| ||||
e)
| Date of the transaction
| 07 November 2017 | ||||
f)
| Place of the transaction
| London Stock Exchange, AIM | ||||
This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.